The Pyrimethamine 0.5 g/Sulfadiazine 10 g/30 mL Oral Liquid is a specially compounded veterinary medication designed for oral use. This formulation combines the antiprotozoal and antibacterial properties of pyrimethamine and sulfadiazine, respectively, to treat a range of infections. The liquid dosage form ensures ease of administration for animals that may have difficulty swallowing pills or tablets, making it ideal for use in veterinary patients, including those in pediatric or geriatric populations.
This medication is primarily indicated for the treatment of toxoplasmosis, a disease caused by the protozoan parasite Toxoplasma gondii. It may also be used in the management of other protozoal infections as determined by a veterinarian. The combination of pyrimethamine and sulfadiazine works synergistically to inhibit folate synthesis in the parasite, thereby halting its replication and spread.

Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a veterinarian's order for one animal patient. Not FDA-approved.
Sulfadiazine is in FDA-approved animal drugs, always in combination. Animal Drugs@FDA lists sulfadiazine with trimethoprim (for example Tribrissen and Di-Trim products for dogs, and EQUISUL-SDT for horses), sulfadiazine with pyrimethamine (ReBalance, for horses) and silver sulfadiazine with enrofloxacin in ear products. EQUISUL-SDT is labeled for lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subsp. zooepidemicus, and ReBalance for equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona. The Merck Veterinary Manual explains that trimethoprim and a sulfonamide together produce a sequential blockade of bacterial enzyme systems. Compounded preparations are not FDA-approved and are dispensed only on a veterinarian's prescription for an individual animal.
The EQUISUL-SDT label says not to use it in horses allergic to sulfonamides or trimethoprim, warns that antimicrobials given to stressed horses may cause sudden, sometimes fatal diarrhea, and advises stopping if diarrhea or blood count or clotting changes appear. The ReBalance label warns of bone marrow suppression and anemia. The Merck Veterinary Manual lists dry eye (keratitis sicca) as a recognized adverse effect of sulfonamides, along with allergic reactions such as hives, rashes, fever and joint inflammation, and reversible low thyroid function in dogs after high doses. The EQUISUL-SDT label says people with a known sensitivity to sulfonamides or trimethoprim should avoid contact with the product. Ask your veterinarian or pharmacist about other medicines and supplements your animal takes.
21 CFR 530.41(a)(9) prohibits extralabel use of sulfonamide drugs in lactating dairy cattle, except approved use of sulfadimethoxine, sulfabromomethazine and sulfaethoxypyridazine. In other cases, compounding from an approved product is extralabel use permitted under 530.13(b) only when no approved animal or human drug, used as labeled or in conformity with the extralabel criteria of part 530, will, in the available dosage form and concentration, appropriately treat the condition diagnosed, and 530.13(a) excludes compounding from bulk. Sulfadiazine is not on FDA's GFI #256 office stock list; pyrimethamine/sulfadiazine is under review for horses (10/05/2026). The EQUISUL-SDT label links potentiated sulfonamides in pregnancy to congenital abnormalities possibly related to folate deficiency.
Our specially compounded Pyrimethamine 0.5 g/Sulfadiazine 10 g/30 mL Oral Liquid is a veterinary medication designed for ease of administration and optimal patient compliance. This formulation combines two potent antimicrobial agents, pyrimethamine and sulfadiazine, in a liquid form that is particularly beneficial for animals who have difficulty swallowing pills or tablets. Pyrimethamine is a dihydrofolate reductase inhibitor that interferes with folic acid synthesis in parasites. Sulfadiazine, a sulfonamide antibiotic, works by inhibiting bacterial synthesis of dihydrofolic acid, thereby exerting a bacteriostatic effect against a broad spectrum of microorganisms.
The combination of pyrimethamine and sulfadiazine is commonly used in the treatment of a serious and potentially life-threatening infection called toxoplasmosis, which is caused by the protozoan parasite Toxoplasma gondii. This medication may also be indicated for the treatment of other infections where the organisms are susceptible to this combination of antimicrobials. The liquid formulation ensures that the medication can be accurately measured and administered, which is crucial for achieving the desired therapeutic effect while minimizing the risk of toxicity.
It is important for prescribers to consider the specific needs of the patient, including size, species, and health status, when determining the appropriate dosage. Regular monitoring of the patient for therapeutic efficacy and potential adverse effects is recommended. As with all medications, it is essential to follow the prescribed treatment regimen and to consult with a veterinarian if there are any concerns or observed side effects. Our team at Bayview Pharmacy is committed to providing high-quality, custom-compounded medications to meet the unique needs of each veterinary patient. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us.
The combination of pyrimethamine and sulfadiazine in an oral liquid formulation is primarily used in the treatment of toxoplasmosis, a parasitic disease often found in animals and transmissible to humans. Pyrimethamine is a dihydrofolate reductase inhibitor that interferes with folic acid synthesis in the parasite, while sulfadiazine is a sulfonamide antibiotic that inhibits bacterial and protozoal synthesis of dihydrofolic acid. When used together, they exhibit a synergistic effect that enhances the efficacy of the treatment.
It is crucial to be aware of potential drug interactions when administering this combination. Pyrimethamine may interact with other folate antagonists, such as methotrexate or trimethoprim, potentially leading to increased risk of hematologic toxicity. Patients on concurrent therapy with bone marrow suppressants should be monitored closely for signs of myelosuppression. Additionally, pyrimethamine can increase the levels of phenytoin, a common anticonvulsant, which may necessitate an adjustment in the phenytoin dosage to avoid toxicity.
Sulfadiazine, on the other hand, can displace warfarin from plasma protein binding sites, potentially leading to an increased risk of bleeding. Patients on warfarin should have their prothrombin time or INR monitored closely, and dosage adjustments of the anticoagulant may be required. Sulfadiazine may also potentiate the effects of oral hypoglycemic agents and sulfonylureas, increasing the risk of hypoglycemia. It is important to monitor blood sugar levels and adjust the dosages of these medications as necessary.
Both pyrimethamine and sulfadiazine can cause crystalluria and renal damage, which may be exacerbated by concurrent administration of other nephrotoxic drugs such as cyclosporine or aminoglycoside antibiotics. Adequate hydration should be maintained to minimize the risk of crystal formation in the urine. Additionally, the use of this combination with other drugs that can cause bone marrow suppression, such as zidovudine, should be approached with caution, and blood counts should be monitored regularly.
Patients with a known deficiency in glucose-6-phosphate dehydrogenase (G6PD) should use this medication cautiously, as sulfadiazine can cause hemolysis in such individuals. It is also important to note that sulfonamides, including sulfadiazine, can cause severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly in patients with HIV infection.
Given the complexity of potential interactions, prescribers should review the patient's complete medication profile for possible interactions before initiating therapy with this formulation. Patients or prescribers with questions or concerns about the use of this medication or its interactions with other drugs are encouraged to reach out to us for further information and guidance.
The Pyrimethamine 0.5 g/Sulfadiazine 10 g/30 mL Oral Liquid is a veterinary medication specifically compounded to treat infections caused by protozoal parasites, such as Toxoplasma gondii, which can cause toxoplasmosis in animals. This liquid formulation is designed for oral administration, making it particularly suitable for animals that may have difficulty swallowing pills or tablets, such as small or uncooperative pets, or those with esophageal disorders.
Pyrimethamine is an antiparasitic compound that works by inhibiting the dihydrofolate reductase enzyme in parasites. This enzyme is crucial for the synthesis of tetrahydrofolic acid, which is necessary for the production of DNA, RNA, and proteins. By blocking this enzyme, pyrimethamine effectively halts the replication and multiplication of the parasites, thereby limiting the spread of the infection.
Sulfadiazine is a sulfonamide antibiotic that interferes with the synthesis of folic acid in bacteria and protozoa. It competes with para-aminobenzoic acid (PABA), preventing its incorporation into dihydropteroate synthetase, which is essential for the synthesis of folic acid. This action results in the inhibition of bacterial and protozoal growth, as these organisms are unable to take up folic acid from their environment and are dependent on their own synthesis.
When combined, pyrimethamine and sulfadiazine act synergistically to enhance the antiprotozoal effect. The liquid formulation ensures that the active ingredients are well-distributed in the solution, providing consistent dosing with each administration. The concentration of the active ingredients has been carefully calculated to ensure that the prescribed volume of liquid delivers the correct dose to the animal.
This medication should be used under the guidance of a veterinarian, as the dosing may need to be adjusted based on the animal's weight, the severity of the infection, and the response to treatment. It is important to shake the bottle well before each use to ensure the medication is properly mixed. The veterinarian will provide specific instructions on how to administer the medication, which may include the use of a dosing syringe or dropper.
For patients and prescribers considering the use of this formulation, it is important to be aware of potential side effects, which may include gastrointestinal disturbances, hypersensitivity reactions, or hematologic changes. Regular monitoring and follow-up with the veterinarian are essential to ensure the safety and efficacy of the treatment. If you have any questions or concerns about this medication or its administration, please do not hesitate to reach out to us at Bayview Pharmacy for further assistance.
This is a compounded medication in liquid form designed for oral use, combining Pyrimethamine and Sulfadiazine in a 30 mL solution. It is typically prescribed by veterinarians for the treatment of specific infections in animals.
Compounded liquid medications are tailor-made for easy administration, making it more convenient particularly for animals that have difficulty swallowing pills.
It is important to store this medication in a cool, dry place, away from direct sunlight and out of reach of children and pets. Always check the label for specific storage instructions provided by the pharmacy or your veterinarian.
This medication should be given orally as directed by your veterinarian. It can be mixed with food or administered directly into the mouth using a dropper or syringe.
No, this medication should only be given to the animal for which it was specifically prescribed. Dosage and formulation may vary widely depending on the species, age, and health condition of the animal.
As with all medications, side effects are possible. Common side effects can include gastrointestinal upset, such as vomiting and diarrhea, or more serious effects like anemia. Always discuss potential side effects with your veterinarian and observe your pet after administering the medication.
If you miss a dose, give it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double up on doses.
If you suspect that you have given your pet too much of this medication, it is important to contact your veterinarian or an emergency veterinary clinic immediately for advice.
Only your veterinarian can adjust the dosage. Do not change the dose yourself even if you think the medication is not working. Always follow the veterinarian's instructions carefully.
Compounded medications can often be flavored to make them more palatable for your pet. However, acceptability will vary from one animal to another. Consult with your veterinarian or the compounding pharmacy if your pet is having difficulty with the taste.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally